 |
|
|
| |
Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates
|
| |
| |
EASL 2025 May 70-10 Amsterdam
Jin Hong1, Vivek K. Rajwanshi1, Jimmy Lu2, Min Luo1, Hyunsoon Kang1, Kellan Passow1, Jacquelyn Sousa1, Dana Cho1,
John Cortez1, Ji Eun Song1, Lillian Adame1, Cheng Liu1, Sarah Stevens1, Dinah Misner1, Shane Daguison1, Kusum Gupta1,
Aneerban Bhattacharya1, Antitsa Stoycheva1, Rostom Ahmed-Belkacem1, Xuan (Susan) G. Luong1, Lawrence M. Blatt1, Li Sun2,
David B. Smith1, Julian A. Symons1
1 Aligos Therapeutics Inc., 1 Corporate Drive, South San Francisco, CA 94080, USA;
2 Amoytop Biotech Co., No. 330 Wengjiao Road, Haicang, Xiamen, Fujian, P.R. China
|
| |
|
|
|
|
|
